REGN Regeneron Pharmaceuticals
FY2025 10-K
Regeneron Pharmaceuticals (REGN) filed its fiscal year 2025 10-K annual report with the SEC on Feb 4, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development, manufacturing, and commercialization of innovative biologic drugs and drug-delivery devices with regulatory approval focus
- • New emphasis on expanding internal manufacturing capacity and establishing fill/finish capabilities amid production constraints and pandemic-related impacts
Management Discussion & Analysis
- • No revenue or profitability figures provided in the excerpt
- • No segment performance details disclosed
Risk Factors
- • Lease financing $720M matures March 2027, full payment due unless extended with lender consent
- • Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio
Financial SummaryXBRL
Revenue
$14.3B
Net Income
$4.5B
Operating Margin
24.9%
Net Margin
31.4%
ROE
14.4%
Total Assets
$40.6B
EPS (Diluted)
$41.48
Operating Cash Flow
$5.0B
Source: XBRL data from Regeneron Pharmaceuticals FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Regeneron Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.